Back to Directory
Setmelanotide
Metabolic & Weight ManagementMC4R agonist for rare genetic obesity disorders, FDA-approved breakthrough therapy.
Key Benefits
- ✓Treats genetic obesity disorders
- ✓Activates MC4R pathway
- ✓Significant weight loss in responders
- ✓Reduces hunger
- ✓First-in-class mechanism
Dosing Information
Dosage Range
1-3 mg
Frequency
Once daily
Typical Duration
Ongoing
Detailed Protocol
Administered via subcutaneous injection once daily. Dose titrated based on response and tolerance. Requires genetic testing confirming qualifying condition. Prescription only.
About Setmelanotide
Setmelanotide (Imcivree) is a synthetic cyclic peptide that activates melanocortin-4 receptors (MC4R) in the brain. FDA-approved for chronic weight management in rare genetic conditions including POMC, PCSK1, and LEPR deficiency obesity.
Research Notes
FDA-approved in 2020 for rare genetic obesity. Breakthrough therapy designation. Shows dramatic weight loss in patients with MC4R pathway deficiencies.
Potential Side Effects
- •Skin hyperpigmentation (common)
- •Injection site reactions
- •Nausea
- •Headache
- •Spontaneous erections in males
- •Depression
Always consult with a healthcare professional before starting any peptide therapy.